PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals.

Abstract Chronic hepatitis C virus (HCV) infection is a serious public health problem worldwide. China, as the country with the largest number of HCV infections in the world, plays a significant role in eliminating hepatitis C. Due to different financial situations and education background, hepatitis C patients take different actions for their disease treatment and management. Therefore, antiviral treatment status should be attached great importance to learn the medical demand of patients. A nationwide, multicenter survey was conducted from July 2015 to June 2016. Of 1798 inpatients and outpatients with chronic HCV from 56 hospitals participated in the survey. Each patient completed the questionnaire with questions about his/her antiviral therapy status, perception of treatment barriers, and expectations for future treatment. In total 1622 patients, including 1241 with chronic hepatitis C, 344 with cirrhosis, and 37 patients with hepatocellular carcinoma, fulfilled data collection requirements and finally were included in analysis. Overall, up to 30.7% of the patients had not or currently does not intend to receive antiviral therapy. The main reason was expecting more potent and well-tolerance medication (31.5%), followed by the fear of interferon related side effects (27.5%). Multiple regression analysis showed that the patient's annual income, the severity of HCV, and comorbidity were independent predictors of not receiving antiviral therapy. The whole patients were expecting more potent and well tolerance medication available soon. In summary, Peg-IFN/RBV treatment regimen cannot meet the need of patients well, and safe and efficient direct-acting antivirals are urgently needed in mainland China.
PMID
Related Publications

Clinical characteristics and current management of hepatitis B and C in China.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.

Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28834904
OWN - NLM
STAT- In-Process
DA  - 20170823
LR  - 20170823
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 34
DP  - 2017 Aug
TI  - Current treatment status and barriers for patients with chronic HCV infection in 
      mainland China: A national multicenter cross-sectional survey in 56 hospitals.
PG  - e7885
LID - 10.1097/MD.0000000000007885 [doi]
AB  - Chronic hepatitis C virus (HCV) infection is a serious public health problem
      worldwide. China, as the country with the largest number of HCV infections in the
      world, plays a significant role in eliminating hepatitis C. Due to different
      financial situations and education background, hepatitis C patients take
      different actions for their disease treatment and management. Therefore,
      antiviral treatment status should be attached great importance to learn the
      medical demand of patients. A nationwide, multicenter survey was conducted from
      July 2015 to June 2016. Of 1798 inpatients and outpatients with chronic HCV from 
      56 hospitals participated in the survey. Each patient completed the questionnaire
      with questions about his/her antiviral therapy status, perception of treatment
      barriers, and expectations for future treatment. In total 1622 patients,
      including 1241 with chronic hepatitis C, 344 with cirrhosis, and 37 patients with
      hepatocellular carcinoma, fulfilled data collection requirements and finally were
      included in analysis. Overall, up to 30.7% of the patients had not or currently
      does not intend to receive antiviral therapy. The main reason was expecting more 
      potent and well-tolerance medication (31.5%), followed by the fear of interferon 
      related side effects (27.5%). Multiple regression analysis showed that the
      patient's annual income, the severity of HCV, and comorbidity were independent
      predictors of not receiving antiviral therapy. The whole patients were expecting 
      more potent and well tolerance medication available soon. In summary, Peg-IFN/RBV
      treatment regimen cannot meet the need of patients well, and safe and efficient
      direct-acting antivirals are urgently needed in mainland China.
FAU - Bian, Dan-Dan
AU  - Bian DD
AD  - aForm Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University
      bLiver Department, Wu Jieping Medical Foundation, Beijing, China.
FAU - Zhou, Hai-Yang
AU  - Zhou HY
FAU - Liu, Shuang
AU  - Liu S
FAU - Liu, Mei
AU  - Liu M
FAU - Duan, Carol
AU  - Duan C
FAU - Zhang, Jin-Yan
AU  - Zhang JY
FAU - Jiang, Ying-Ying
AU  - Jiang YY
FAU - Wang, Ting
AU  - Wang T
FAU - Chen, Yu
AU  - Chen Y
FAU - Wang, Zhao
AU  - Wang Z
FAU - Zheng, Su-Jun
AU  - Zheng SJ
FAU - Duan, Zhong-Ping
AU  - Duan ZP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
EDAT- 2017/08/24 06:00
MHDA- 2017/08/24 06:00
CRDT- 2017/08/24 06:00
AID - 10.1097/MD.0000000000007885 [doi]
AID - 00005792-201708250-00041 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Aug;96(34):e7885. doi: 10.1097/MD.0000000000007885.